Firm News
Wiggin and Dana Counsels Client Swedish Orphan Biovitrum (Sobi) in its Agreement with Sanofi For Early Opt-In to Hemophilia A Product
On behalf of the Firm, Wiggin and Dana Partner Patti Melick represented Swedish Orphan Biovitrum AB (publ) (Sobi) in its expanded agreement with Sanofi for early opt-in to the development and commercialization of BIVV001, an investigational extended half-life factor VIII therapy with the potential to provide once-weekly dosing for people with hemophilia A. Sobi made a payment to Sanofi of $50 million and will become a development partner in the program. Upon approval in the EU, Sobi will pay the balance of the development costs incurred for BIVV001. Under the agreement, Sobi will pay Sanofi a 9% royalty on direct sales in the Sobi territory (Europe, North Africa, certain countries in the Middle East, and Russia) and receive royalties from Sanofi on direct sales in North America (8%) and other markets (13%) in the Sanofi territory.
To learn more, click here.
